German ADC specialist Tubulis closed a landmark Series C financing — roughly €308 million (~$356 million) — to accelerate clinical development of its lead ADC, TUB‑040, and expand programs into additional indications and earlier‑line settings. The raise ranks among the largest private financings for an ADC-focused company in Europe and reflects investor appetite for differentiated payload and linker engineering approaches. Tubulis said proceeds will support expanded trials and biomarker work ahead of data readouts scheduled for upcoming oncology meetings. The company emphasizes in‑house design and manufacturing control to optimize drug‑to‑antibody ratios and therapeutic index. For the ADC field, the deal signals continued capital availability for platform players solving historical toxicity and payload delivery challenges. Competitors and potential partners will watch upcoming clinical safety and efficacy signals to assess whether Tubulis’ engineered ADCs can meaningfully broaden ADC utility across solid tumors.